68Ga-PSMA-I&T与前列腺癌细胞特异性结合的研究

doi:10.12092/j.issn.1009-2501.2020.12.001

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (12): 1321-1329.doi: 10.12092/j.issn.1009-2501.2020.12.001

• 基础研究 • 下一篇

⁶⁸Ga-PSMA-I&T与前列腺癌细胞特异性结合的研究

谢彦^1,2，李澄¹，张露露²，赵震宇²，黄珊珊¹，王永生¹，汤元翔¹，王峰²

¹东南大学附属中大医院核医学科，南京 210009，江苏；²南京医科大学附属南京第一医院核医学科，南京 210006，江苏

收稿日期:2020-10-09 修回日期:2020-11-20 出版日期:2020-12-26 发布日期:2021-01-04
通讯作者: 王峰，男，博士，主任医师，博士生导师，研究方向：肿瘤核素显像与治疗。 Tel: 18951670836 E-mail: fengwangcn@hotmail.com
作者简介:谢彦，女，博士在读，主治医师，研究方向：肿瘤核素显像与治疗。 Tel: 13512519376 E-mail: 573358569@qq.com
基金资助:
国家自然科学基金项目（11805104）；江苏省重点研发专项基金（BE2017612）；江苏省卫健委医学科研项目（H2019091）

Study on the specific binding of 68Ga-PSMA-I&T to prostate cancer cells

XIE Yan ^1,2, LI Cheng ¹, ZHANG Lulu ², ZHAO Zhenyu ², HUANG Shanshan ¹, WANG Yongsheng¹, TANG Yuanxiang ¹, WANG Feng ²

¹ Department of Nuclear Medicine, Zhongda Hospital, Southeast University, Nanjing 210009, Jiangsu, China; ²Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, Jiangsu, China

Received:2020-10-09 Revised:2020-11-20 Online:2020-12-26 Published:2021-01-04

摘要/Abstract

摘要： 目的：合成前列腺特异性膜抗原（PSMA）靶向诊断药物68Ga-PSMA-I&T并探讨其与前列腺癌LNCaP细胞特异性结合。方法：合成68Ga-PSMA-I&T，检测其标记率、放化纯及稳定性。用2-PMPA和68Ga-PSMA-I&T与LNCaP细胞竞争性结合，计算不同时间点细胞的放射性摄取值。用不同浓度PSMA-I&T和68Ga-PSMA-I&T与LNCaP细胞竞争性结合，计算细胞的放射性摄取值。进行68Ga-PSMA-I&T在ICR小鼠体内生物分布实验，计算每克组织放射性摄取值。对ICR小鼠和LNCaP荷瘤鼠行68Ga-PSMA-I&T micro-PET/CT动态显像，绘制时间放射性摄取值曲线。切除荷瘤鼠的肿瘤组织进行免疫化学染色，观察PSMA的表达情况。结果：68Ga-PSMA-I&T标记率为（95.4±2.5）%，放化纯大于99%，体内外稳定性好。结合组、阻断组反应30 min、90 min时细胞放射性摄取值分别为（3.3±0.5）%、（10.2±0.4）%、（0.99±0.03）% 和（1.54±0.05）%（P<0.001），PSMA-I&T的半抑制浓度（IC50）为38.64 nmol/L。荷瘤鼠68Ga-PSMA-I&T micro-PET/CT动态显像示15 min肿瘤组织已有明显放射性摄取，并且肿瘤组织的放射性摄取随时间延长逐渐增加。免疫化学染色结果显示LNCaP荷瘤鼠离体肿瘤组织表达丰富的PSMA蛋白。结论：68Ga-PSMA-I&T合成过程简便易行，标记率和放化纯高，稳定性好；68Ga-PSMA-I&T能与LNCaP细胞特异性结合，体内分布良好，是理想的前列腺癌靶向诊断示踪剂。

关键词: ⁶⁸Ga-PSMA-I&T, 前列腺癌, 特异性结合, 诊断

Abstract: AIM: To synthesize 68Ga-PSMA-I&T for targeted diagnosis of prostate specific membrane antigen (PSMA) and explore its specific binding to LNCaP cells of prostate cancer. METHODS: 68Ga-PSMA-I&T was synthesized and its labeling rate, radiochemical purity and stability were measured. LNCaP cells were competitively bound with 2-PMPA and 68Ga-PSMA-I&T, and the radioactive uptake values of cells at different time points were calculated. LNCaP cells were then competitively combined with 68Ga-PSM-I&T and PSM-I&T at different concentrations, and the values of cell radioactive uptake values were calculated. The biological distribution experiment of 68Ga-PSM-I&T in ICR mice was conducted, and the radioactive uptake values per gram of tissue were calculated. Dynamic imaging with 68Ga-PSM-I&T micro-PET/CT was performed on ICR mice and LNCaP tumor-bearing mice, and the time radioactive uptake value curve was plotted. Immunochemical staining was performed to observe the expression of PSMA in the tumor tissues of mice. RESULTS: The radioactive labeling rate of 68Ga-PSMA-I&T was (95.4±2.5)%, with the purity more than 99% and the stability in vitro and in vivo was good. The radioactive uptake values of cells at 30 min and 90 min in the binding group and the blocking group were (3.3±0.5)%, (10.2±0.4)%, (0.99±0.03)%, and (1.54±0.05)%, respectively (P<0.001). The semi-inhibitory concentration (IC50) of PSMA-I&T was 38.64 nmol/L. The dynamic imaging of 68Ga-PSMA-I&T micro-PET/CT of tumor-bearing mice showed significant radioactive uptake in tumor tissues at 15 min, with the radioactive uptake of tumor tissues gradually increased with time. Immunochemical staining results showed that the expression of PSMA protein was abundant in the isolated tumor tissues of LNCaP tumor-bearing mice. CONCLUSION: The synthesis of 68Ga-PSMA-I&T was simple and easy, and its radioactive labeling rate and radiochemical purity were high and its stability was good. 68Ga-PSMA-I&T can specifically bind to LNCaP cells, and its distribution in vivo is good. It shows that it is an ideal tracer for targeted diagnosis of prostate cancer.

Key words: ⁶⁸Ga-PSMA-I&T, prostate cancer, specific binding, diagnosis

中图分类号:

R965.2

谢彦, 李澄, 张露露, 赵震宇, 黄珊珊, 王永生, 汤元翔, 王峰. ⁶⁸Ga-PSMA-I&T与前列腺癌细胞特异性结合的研究[J]. 中国临床药理学与治疗学, 2020, 25(12): 1321-1329.

XIE Yan, LI Cheng, ZHANG Lulu, ZHAO Zhenyu, HUANG Shanshan, WANG Yongsheng, TANG Yuanxiang, WANG Feng. Study on the specific binding of 68Ga-PSMA-I&T to prostate cancer cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1321-1329.

[1]	丁昊, 高振华, 郑云. microRNA在前列腺癌诊断和治疗方面的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(6): 696-708.
[2]	陈云杰, 周旋, 张元斌, 王旭, 林珠, 朱素燕. ErbB2在心脏疾病中作用的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(10): 1182-1189.
[3]	李雁鹏, 赵正卿, 王雯雯, 庄建华, 赵忠新. 慢性失眠临床诊断与药物治疗研究现状[J]. 中国临床药理学与治疗学, 2021, 26(5): 487-490.
[4]	赵显超, 任佳封, 孙述昱, 宿长军. 不宁腿综合征临床特点与规范化治疗[J]. 中国临床药理学与治疗学, 2021, 26(5): 497-503.
[5]	魏松长, 杨红琪, 张宏娟, 施晓丽, 任凯文. RON蛋白与CXC趋化因子受体4蛋白的表达与去势抵抗型前列腺癌患者阿比特龙耐药的相关性[J]. 中国临床药理学与治疗学, 2021, 26(4): 414-422.
[6]	谢彦, 李澄, 张露露, 俞飞, 臧士明, 付晶晶, 刘璐, 王峰. ⁶⁸Ga-PSMA-I&T与初诊前列腺癌病灶结合的研究[J]. 中国临床药理学与治疗学, 2021, 26(12): 1379-1385.
[7]	彭福生, 黄小惠, 李鹏, 汤建儿. miR-34a通过调控雄激素受体基因抑制前列腺癌细胞系LNCaP增殖[J]. 中国临床药理学与治疗学, 2021, 26(1): 10-17.
[8]	曹颖, 屠凌岚, 王孝举, 郑晓亮. 前列腺癌细胞内TMPRSS2-ERG融合基因产物转录调控机制研究进展[J]. 中国临床药理学与治疗学, 2020, 25(7): 791-795.
[9]	徐胜华，高卓，王建锋. 多糖染料木素复合多糖脂质体的制备及其抗前列腺癌机制的研究[J]. 中国临床药理学与治疗学, 2020, 25(4): 393-400.
[10]	黄后宝. PROfound研究——前列腺癌精准治疗新希望[J]. 中国临床药理学与治疗学, 2020, 25(2): 144-150.
[11]	李文书，董淮富. 血清降钙素原在细菌性脑膜炎中的价值[J]. 中国临床药理学与治疗学, 2019, 24(11): 1315-1320.
[12]	蔡海瑞，程淑清，刘喜娟，陈安儿. 妊娠期妇女甲状腺功能检测在子痫前期的诊断价值研究[J]. 中国临床药理学与治疗学, 2019, 24(1): 71-76.
[13]	王婷，陈珂，周长平，王义桥，鲁显福，李元海. 精准麻醉对机器人辅助腹腔镜前列腺癌根治术患者围术期细胞免疫功能的影响[J]. 中国临床药理学与治疗学, 2018, 23(2): 175-179.
[14]	何苗，范晶，王子卫，赵和照. 胃肠间质瘤临床诊治现状与进展[J]. 中国临床药理学与治疗学, 2017, 22(11): 1315-1320.
[15]	浦春, 陶青松，朱翔，秦明明，武其文，冯钢. 三种心肌损伤标志物在急性心肌梗死早期诊断中的应用价值[J]. 中国临床药理学与治疗学, 2017, 22(1): 82-86.

⁶⁸Ga-PSMA-I&T与前列腺癌细胞特异性结合的研究

Study on the specific binding of 68Ga-PSMA-I&T to prostate cancer cells

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价